A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Carcinoma, Squamous Cell of Head and Neck
Malignant Melanoma

Interventions

DRUG: PF-05082566
DRUG: rituximab
DRUG: PF-05082566

Sponsor

Pfizer